Middle Cerebral Artery Aneurysm Trial

Launched by UNIVERSITY OF ALBERTA · Dec 16, 2021

Keywords

ClinConnect Summary

The Middle Cerebral Artery Aneurysm Trial is studying the best ways to treat aneurysms located on the middle cerebral artery (MCA), which is an important blood vessel in the brain. These aneurysms can be treated with surgery or non-surgical methods, but doctors are not sure which is better for patients. The trial aims to gather more information to help determine the most effective treatment options for patients with this condition.

To participate in the trial, individuals must be at least 18 years old and have a documented aneurysm on the MCA, either from a recent rupture or one that has not burst yet. Participants will be evaluated by their medical team to see if they are suitable for either surgical or non-surgical treatment options. Throughout the trial, participants can expect to receive careful monitoring and care as researchers compare the outcomes of different treatment methods. This study will help improve future care for patients with MCA aneurysms and provide clearer guidance for treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients at least 18 years of age
• • At least one documented, intradural, intracranial aneurysm anywhere on the course of the MCA vessel, ruptured or unruptured. An untreated ruptured aneurysm (with delay in diagnosis) which is suspected to have occurred more than 30 days prior to study inclusion will be considered an unruptured aneurysm
• • In the case of SAH, WFNS grade 4 or less
• • The patient and aneurysm are considered appropriate for either surgical or endovascular treatment by the treating team
• Exclusion Criteria:
• • Patients with absolute contraindications administration of contrast material (any type)
• • Patients with AVM-associated aneurysms
• • Patients or caregivers unable to provide consent
• • Poor grade (WFNS 5) ruptured aneurysms